Current SATVI news
Dr Michèle Tameris, has co-authored a book chapter titled "Between representing and intervening: Diagnosing childhood tuberculosis during a vaccine trial in South Africa".
Dr Angelique Luabeya has been awarded "C" rating from the National Research Foundation.
The interim Dean of the UCT Faculty of Health Sciences has just announced that SATVI Senior Research Officer, Elisa Nemes has been promoted to Associate Professor.
TB Science Official Press Conference: Watch announcement of final results from M72/AS01E candidate vaccine against tuberculosis (TB) online.
Press Conference: Towards a TB Vaccine, Union World Conference, 29 October 2019: Watch press conference where the final results M72/AS01E candidate vaccine against tuberculosis (TB) were announced at the Union Conference on Lung Health, India.
Results from the MM72/AS01E TB vaccine study have been presented at the Union Conference on Lung Health, India.
SATVI is calling for applicants to the position of Laboratory Technologist at its Worcester field site. NOW CLOSED.
SATVI researchers Professors Mark Hatherill, Tom Scriba, Dr Bilek, Darboe, Mbandi, Penn-Nicholson have co-authored a research article titled "Plasma Type I IFN Protein Concentrations in Human Tuberculosis." appearing in the Frontiers in Cellular and Infection Microbiology.
Professor Mark Hatherill has co-authored a journal article titled "FDG-PET/CT as a non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis" appearing in the Journal of Nuclear Medicine.
Professor Mark Hatherill has co-authored a journal article titled: "FDG-PET/CT as a non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis" appearing in the Journal of Nuclear Medicine.
We are inviting applications for a postdoctoral fellowship in human immunology to conduct research aimed at identifying lung immune signatures of resistance to natural M.tb infection in a multi-cohort study. NOW CLOSED.
SATVI researchers have just published an article titled: "Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial" appearing in the Lancet Respiratory Medicine journal.